

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA MERCHANTS CHINA DIRECT INVESTMENTS LIMITED

招商局中國基金有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 133)

ADDITIONAL INVESTMENT IN IFLYTEK HEALTHCARE

Reference is made to the announcement of China Merchants China Direct Investments Limited (the “**Company**”) dated 30 December 2019 in relation to the acquisition of 3% of the ordinary shares of 安徽科大訊飛醫療信息技術有限公司 (Anhui iFlytek Healthcare Information Technology Co., Ltd.*, “**iFlytek Healthcare**”) by 深圳市天正投資有限公司 (Shenzhen Tian Zheng Investment Co., Ltd.*, “**Tian Zheng**”), a wholly-owned subsidiary of the Company, at the consideration of RMB60,000,000 (the “**First Investment**”). The relevant formalities of the First Investment were duly completed in February 2020.

The Company announces that Tian Zheng entered into a share transfer agreement dated 3 November 2021 in relation to a transfer of shares in iFlytek Healthcare, pursuant to which Tian Zheng agreed to further acquire 0.7143% of the ordinary shares of iFlytek Healthcare from 安徽科訊創業投資基金合夥企業(有限合夥)(Anhui Iflytek Venture Capital LLP*), a present shareholder of iFlytek Healthcare, at the consideration of RMB50,000,000 (the “**Further Investment**”). Tian Zheng paid RMB50,000,000 as consideration of the Further Investment on 12 November 2021 and the relevant formalities of the Further Investment were duly completed in recent days. Together with the First Investment, Tian Zheng now owns, in aggregate, 3.7143% of the ordinary shares of iFlytek Healthcare.

Recent Business Developments of iFlytek Healthcare

Based on the international leading intelligent speech and artificial intelligence (AI) technology accumulated by 科大訊飛股份有限公司 (Iflytek Co., Ltd.*) for more than two decades, iFlytek Healthcare has established functional modules such as AI assisted diagnosis, guided medical consultation, speech electronic medical records, image recognition and outbound follow-up calls with the core technologies of cognitive intelligence, autonomous machine learning and reasoning, speech recognition and image recognition in the field of smart hospitals and grass-roots-level medical AI applications, achieving remarkable results in enhancing the level of intelligence and informatisation of hospitals and improving the ability of grass-roots-level doctors to provide medical treatment.

iFlytek Healthcare is committed to “serve a Healthy China with AI” by its best efforts to integrate AI technology into the medical industry, creating the new blue ocean of “AI plus Healthcare” and promoting the development of the healthcare industry in order to facilitate the implementation of the national healthcare reform policy. Up to present, iFlytek Healthcare has started to build up large-scale application and achieved significant sales revenue during the past two years.

For and on behalf of
CHINA MERCHANTS CHINA DIRECT
INVESTMENTS LIMITED

WANG Xiaoding

Director

Hong Kong, 3 December 2021

** For identification purposes only*

As at the date hereof, the Executive Directors of the Company are Mr. WANG Xiaoding, Mr. TSE Yue Kit and Ms. KAN Ka Yee, Elizabeth; the Non-executive Directors are Mr. ZHOU Xing, Mr. ZHANG Rizhong and Mr. KE Shifeng; and the Independent Non-executive Directors are Mr. LIU Baojie, Mr. TSANG Wah Kwong, Dr. LI Fang, Dr. GONG Shaolin and Mr. Michael Charles VITERI.